Established in September 1991, we currently have facilities and staff in the U.S. and Europe. Our corporate headquarters, Cell Therapeutics, Inc. (CTI) are in Seattle, Washington with research and development facilities at our Italian branch in Bresso (Milan), Italy.

Our wholly-owned subsidiaries are Systems Medicine LLC with offices in Scottsdale, AZ, and Aequus BioPharma, Inc. also in the Seattle area.

We support our committed professionals with state-of-the-art facilities and laboratories. We recognize the value of each of our employees and take pride in creating a positive work environment. Our strength lies in the individuals who work to accomplish our collective goals.

Biographies

John H. Bauer became a Director of CTI in October 2005. Mr. Bauer, a leading financial executive, was formerly EVP of Finance for Nintendo of America Inc. While at Nintendo of America Inc., he had direct responsibility for all administrative and finance functions. He is currently serving as a consultant to Nintendo of America Inc. In addition, he serves as an executive advisor and chief financial officer at DigiPen Institute of Technology, a privately-owned accredited computer science, simulation and game development school in Redmond.

For more than thirty years, Mr. Bauer was with Coopers & Lybrand (currently PricewaterhouseCoopers) where in 1979 he was appointed managing partner for the Northwest region. Mr. Bauer was a member of Coopers & Lybrand’s Firm Council, the senior policy making and governing board for the firm. In addition to management responsibilities, he served as the business assurance (audit) practice Partner. Bauer, 64, currently resides in Seattle, Washington.

back to top

James A. Bianco, M.D. is the principal founder of Cell Therapeutics, Inc. and served as the Company's President and Chief Executive Officer and Director from February 1992 to July 2008. With the addition of Craig W. Philips as President in August 2008, Dr. Bianco now serves as CTI’s CEO and Director.

Dr. Bianco has been responsible for securing nearly $1 billion in operating ®in 2000, Novuspharma's pixantrone in 2003, worldwide license and co-development agreement for development and commercialization of OPAXIO™ (formerly branded as XYOTAX) with Novartis in 2006, and the acquisitions of Systems Medicine and worldwide rights to brostallicin in 2007. He brought CTI back into the commercial arena in late 2007 with the acquisition of Zevalin®, approved by the FDA in February 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Prior to joining CTI, Dr. Bianco was an Assistant Member in the clinical research division of the Fred Hutchinson Cancer Research Center (FHCRC) and an Assistant Professor of Medicine at the University of Washington. From 1990 to 1992, Dr. Bianco was the director of the Bone Marrow Transplant Program at the Veterans Administration Medical Center in Seattle. He received his B.S. in Biology and Physics from New York University and his M.D. from Mount Sinai School of Medicine in New York.

Dr. Bianco received the 2005 Corporate Visionary Award from Gilda’s Club Seattle, an organization where people with cancer and their families can receive emotional and social support. “Dr. Bianco has made it his life’s mission to make cancer more treatable by pursuing less toxic and more effective chemotherapy drugs,” said Anna Gottlieb, founder and executive director of Gilda’s Club Seattle. “He also understands that people living with cancer need more than medicine. His support of Gilda’s Club Seattle is actually helping to make cancer more livable.”

And, in a region that boasts some of this nation's leading companies, James Bianco was named CEO of the Year for 2000 by Washington CEO magazine.

back to top

Louis A. Bianco is a founder of CTI and has been CTI's Executive Vice President, Finance and Administration since February 1, 1992, and a Director of CTI from the Company's inception in September 1991 to April 1992, and from April 1993 to April 1995. From January 1989 through January 1992, Mr. Bianco was a Vice President at Deutsche Bank Capital Corporation in charge of risk management. Mr. Bianco is a Certified Public Accountant and received his M.B.A. from New York University.

back to top

Dan Eramian joined CTI as Executive Vice President, Corporate Communications in March 2006. Eramian will serve as a member of the Company’s senior management team and will be responsible for developing and implementing the internal and external communications strategy. Eramian brings nearly 13 years of experience in the biotechnology industry to the position.

Most recently Eramian was Vice President of Communications at BIO, a Washington, DC-based industry organization representing more than 1,200 biotechnology companies, academic institutions, state biotechnology centers, and related organizations. Prior to BIO, Eramian was Assistant Administrator of Communications at the Small Business Administration and Director of Public Affairs at the Department of Justice and Chief Spokesman for the Attorney General. Previously, Eramian served as Chief of Staff to the Senate Leader in the Massachusetts Legislature, and was also Executive Editor of Suburban World Newspapers in the Boston area. He holds a B.A. in English Literature from UMass/Amherst and an M.P.A. from Suffolk University.

back to top

Vartan Gregorian, Ph.D. is the twelfth president of Carnegie Corporation of New York, a grant-making institution founded by Andrew Carnegie in 1911. Prior to his current position, which he assumed in June 1997, Gregorian served for nine years as Brown University's sixteenth president.

He was awarded a Ph.D. in history and humanities from Stanford in 1964. He was founding dean of the Faculty of Arts and Sciences at the University of Pennsylvania in 1974 and four years later became its twenty-third provost. He served as president of the New York Public Library from 1981 to 1989, when he left to become president of Brown.

A Phi Beta Kappa and a Ford Foundation Foreign Area Training Fellow, he is a recipient of numerous fellowships, including those from the John Simon Guggenheim Foundation, the American Council of Learned Societies, the Social Science Research Council and the American Philosophical Society. He is also a fellow of the American Academy of Arts and Sciences. He serves on the boards of the Institute for Advanced Study at Princeton, Human Rights Watch, McGraw Hill Inc., and the Museum of Modern Art, among others. He has been decorated by the French, Italian, Austrian, and Portuguese governments.

His numerous civic and academic honors include some fifty honorary degrees, including those from Brown, Dartmouth, Drew, Johns Hopkins, University of Pennsylvania, the Jewish Theological Seminary, the City University of New York, Rutgers, Tufts, New York University, University of Aberdeen, and, most recently, The Juilliard School, and the University of Illinois at Urbana-Champaign. In 1986 Gregorian was awarded the Ellis Island Medal of Honor and in 1989 the American Academy and the Institute of Arts and Letters' Gold Medal for Service to the Arts. In 1998 President Clinton awarded him the National Humanities Medal, and in 2004 President Bush presented him with the Presidential Medal of Freedom.

back to top

Jeff Jacob joined CTI's management team with our acquisition of Systems Medicine in July 2007. He is a founder of Systems Medicine, and serves as its Chief Executive Officer. Jacob's career spans nearly 20 years in venture capital and early stage technology venture development. Jeff is a founding Board Member of C-PATH Institute, a startup non profit institute co-founded by the FDA, University of Arizona, and SRI International to develop research and educational programs to accelerate drug development.

Jacob has a Master's degree in Engineering and a Master's degree in Technology and Policy from Massachusetts Institute of Technology, as well as a Bachelor's degree in Engineering from the University of Arizona.

back to top

Richard L. Love has 40 years of industry experience, with more than 27 years of leadership roles in the biosciences industry. He started two biopharmaceutical companies, Triton Biosciences Inc. (Alameda, CA) and ILEX Oncology Inc. (ILXO, San Antonio, TX) and served as CEO in both companies for periods of eight years each. In addition Love has served in senior executive positions at not-for-profit organizations, including the Cancer Therapy and Research Center in San Antonio, and the Translational Genomics Research Institute (TGen) in Phoenix.

At Triton and ILEX, Love led teams that were responsible for the clinical development of four important therapeutic products that are currently in the practice of medicine: Betaseron® for patients with multiple sclerosis, Fludara® and CAMPATH® both for patients with chronic lymphocytic leukemia, and Clolar® for acute leukemias. In 2004 ILEX was acquired by Genzyme Corporation for approximately $1B.

Currently Love is a managing partner in Translational Accelerator LLC, an Arizona-based venture capital investment firm, and also serves on the Boards of PAREXEL International (PRXL), ImaRx Therapeutics (IMRX), and Molecular Profiling Institute.

back to top

Mary O'Neil Mundinger, D.P.H., has been a Director since April 1997. Since 1986, she has been Dean and Professor, School of Nursing and Associate Dean, Faculty of Medicine, Columbia University.

Dr. Mundinger is a nationally recognized health policy specialist and was recently named as Columbia's Centennial Professor in Health Policy, the first of its kind at a nursing school. She is a cum laude graduate of the University of Michigan and received her doctorate from Columbia's School of Public Health.

back to top

Phillip M. Nudelman, Ph.D., has been a Director of CTI since March 1994. In April 2000, Dr. Nudelman was named President and Chief Executive of The Hope Heart Institute, Seattle's leading nonprofit cardiovascular research and education center. Nudelman recently retired as President and CEO of Group Health Cooperative and as Chairman and President of Kaiser/Group Health.

A leader in improving health care in the country, Nudelman has served on the White House Task Force for Health Care Reform and the President's Advisory Commission on Consumer Protection and Quality in Health Care. He has served on the Pew Health Professions Commission and the AMA Task Force on Ethics, currently surves as Chairman of the American Association of Health Plans. Nudelman also serves on the boards of directors of Cytran Ltd., SpaceLabs Medical Inc., and PersonalPath.com, Inc.

back to top

Gabriella Pezzoni, Ph.D. was named Scientific Director of CTI's Italian branch in September 2006 with responsibility for preclinical research and development. She was a founding member of the Italian pharmaceutical company Novuspharma with responsibility as Director of Biology prior to its merger with CTI. Before joining Novuspharma, Dr. Pezzoni was head of oncology research at Boehringer Mannheim Italia SpA., where she was responsible for New Drug Applications and Investigational New Drug applications. Before joining Boehringer Mannheim Italia she worked at Farmitalia Carlo Erba Research Centre in Nerviano, Milano (ex Pfizer Inc.) coordinating in vivo anti-tumor activity studies. Dr. Pezzoni has also worked at the Tumour Institute in Milan and holds a degree in biological sciences from the University of Pavia.

back to top

Craig W. Philips assumed his role as CTI's President in August 2008. In that role, he manages the company’s day-to-day drug development and commercial operations. Prior to joining CTI, Philips was Vice President and General Manager of Bayer Healthcare Oncology. Since 2006, Philips has been leading Bayer's U.S. oncology operations following the integration of the U.S. oncology businesses from Berlex and Bayer. In this capacity, he oversaw the U.S. oncology operations with sales of $350 million and a staff of over 150. Philips was also either a member or chair of alliance executive committees which included Onyx, Novartis, Genzyme, and Favrille.

Prior to Bayer Healthcare, Philips was the head of Berlex Oncology since 2004. He was responsible for the U.S. oncology operations with sales of more than $160 million. Before Berlex, Philips was with Schering Plough in U.S., and international roles. He began his career with Bristol Myers, where he worked in a variety of therapy areas including oncology, cardiology, and CNS.

back to top

Mauro G. Premi joined CTI in April 2006 as Finance and Administration Director. He now serves as General Manager for the European branch leading the Bresso Senior Management Team. Before joining CTI, Mr. Premi covered interim Finance Director positions for special projects at Varta (Rayovac Group), Cooper Cameron, and CMGRP (IPG Group).

Mr. Premi gained a strong background in finance, controlling, and general management functions while covering various managerial positions in multinational companies, including Pall Corp. and Demag (former Mannesmann Group, later Siemens). With the latter company and its Italian subsidiaries, Mr. Premi spent more than 10 years working in Germany, and was promoted to the position of Group Finance and Controlling Director in Italy. He had full responsibility for finance (Italian, German and US GAAP), planning and controlling, as well as general administration. He was directly responsible at different times for various special operations such as start-up, acquisitions, and selling of companies and/or operative branches.

Mr. Premi, graduated in Business Administration from L. Bocconi University, Milano, Italy and has taken business management courses in the UK, Germany, and the US.

back to top

Jack W. Singer, M.D., is a founder and Director of CTI and was appointed Chief Medical Officer in January 2004. Dr. Singer was formerly Executive Vice President, Research Program Chair. As Chief Medical Officer, Dr. Singer is the primary thought leader for CTI clinical and medical strategy. He is a noted expert in hematologic cancers, having developed the clonal theory of leukemia. He has authored more than 240 peer-reviewed manuscripts and 13 chapters in textbooks on cell biology and clinical drug development and holds 14 patents. He has been an invited speaker at numerous medical conferences, including, the 6th International Symposium on Polymer Therapeutics, and he is a member of the Society for Clinical Investigation.

Prior to joining CTI, Dr. Singer was Professor of Medicine at the University of Washington and full Member of the Fred Hutchinson Cancer Research Center. From 1975 to 1992, he was the Chief of Medical Oncology at the Veterans Administration Medical Center in Seattle. In addition, Singer served as an advisor to the National Cancer Institute and was a consultant to several pharmaceutical companies prior to joining CTI.

back to top

Frederick W. Telling, Ph.D. joined CTI's Board in December 2006. Dr. Telling is former Vice President of Corporate Policy and Strategic Management for Pfizer Inc and was elected a corporate officer of Pfizer in 1994. He joined Pfizer in 1977 and was responsible for strategic planning and policy development throughout the majority of his career.

Dr. Telling’s professional career has focused on the areas of health policy, innovation, education and research. He is Vice Chairman for the American Foundation for Pharmaceutical Education and an invited faculty lecturer at the Harvard University School of Public Health and Cornell University. He is involved in the work of the Council on Competitiveness, the Business Roundtable, the National Association of Manufacturers, and the Institute of Medicine, where he was a contributing author to the IOM’s series on Technology Innovation in Medicine. He is a member of the Board of the Alliance for Aging Research, Biotechnology Industry Organization (BIO - Executive Committee), the California Health Care Institute, the New England Healthcare Institute (Vice Chairman), Committee for Economic Development (Vice Chairman), Healthy Florida Foundation, March of Dimes National Foundation Board, The Montrose Group, ORBIS, New York Biotechnology Association (NYBA), and United Hospital Fund.  

Dr. Telling received his BA from Hamilton College and his Master’s of Industrial and Labor Relations and Ph.D. in Economics and Public Policy from Cornell University.

back to top

Tim Williamson joined CTI's management team with our acquisition of Systems Medicine in July 2007. He is a founder of System Medicine and serves as its Chief Business Officer. Williamson's career spans 30+ years in large-cap pharma (Merck and Boehringer Mannheim), large-cap biotech (Genentech), start-up biotech (ILEX and DirectGene) and consulting. He has experience building the links and infrastructure necessary to bring innovative biotech products to market through his thorough understanding of pharmaceutical company needs and capabilities, including experience marketing new products, negotiating international product licensing agreements, building sales and marketing organizations, and building a successful start-up company from scratch (i.e., ILEX Oncology where he was one of the first three employees).

Williamson has played key roles in the development and launch of such products as Merck's first recombinant vaccine, Genentech's recombinant human growth hormone (rHGH) and recombinant tissue plasminogen activator (rTPA), and ILEX's humanized monoclonal antibody, CAMPATH. Prior to joining Systems Medicine, Williamson negotiated numerous product deals and alliances including ILEX's agreement giving Schering AG worldwide distribution rights to CAMPATH in return for $30.0 million in fees and milestones, 60% of the profit in the U.S. and a royalty comparable to 60% profit in the rest of the territory (The Pink Sheet, 08/30/99, p. 21).

back to top

Posted August 1, 2008

Copyright © 2004-2008 Cell Therapeutics, Inc., Seattle, WA, USA. All rights reserved. "Making cancer more treatable" is a registered mark of CTI.